Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 10  |  Issue : 38  |  Page : 118-124

Leucas aspera inhibits the Dalton's ascitic lymphoma in Swiss albino mice: A preliminary study exploring possible mechanism of action


1 Laboratory of Tumor Pharmacology, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Guwahati, Assam, India
2 Department of Pharmaceutics, Girijananda Institute of Pharmaceutical Sciences, Azara, Guwahati, Assam, India
3 Department of Pathology, Gauhati Medical College, Guwahati, Assam, India
4 Department of Pharmacology, College of Pharmaceutical Sciences, Medical College, Trivandrum, India

Correspondence Address:
Bibin Baby Augustine
Laboratory of Tumor Pharmacology, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Guwahati - 781 032, Assam
India
Login to access the Email id

Source of Support: NIPER-Guwahati, Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, Government of India, Conflict of Interest: None


DOI: 10.4103/0973-1296.131022

Rights and Permissions

Background: North East India is a rich source of medicinal plants and a number of plant extracts are used by tribal peoples living in this area for various disorders. L.aspera is such a plant, traditionally used as an antitumor agent. Aim: In the present study, aerial parts of L.aspera were investigated for antitumor activity in Dalton's lymphoma (DAL) bearing mice. The ability of plant extract in free radical scavenging, neoangiogenesis inhibition and macrophage stimulation were also checked. Materials and Methods: Based on the preliminary in vitro cytotoxicity studies ethyl acetate fraction of L.aspera (EALA) was selected for the detailed study. DAL ascites tumor model was performed to check the antitumor activity of EALA (200 and 400mg/kg of body weight). Hematological and histopathological parameters were estimated. Antioxidant levels, neoangiogenesis and peritoneal macrophage count were also determined. Results: In vitro MTT and Trypan blue assay results showed the cytotoxic effect of EALA in DAL cells lines. EALA treatment resulted in significant decrease in ascites tumor volume and viable cell count. Hematological and liver antioxidant parameters were normalised by EALA treatment. It was also found that EALA treatment inhibits neovascularisation and produce macrophage stimulation in treated mice. Conclusion: The results showed that EALA is a promising anticancer agent and its activity is comparable to the standard drug 5-Flouro uracil (5-FU).


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1756    
    Printed60    
    Emailed4    
    PDF Downloaded30    
    Comments [Add]    
    Cited by others 2    

Recommend this journal